Glipizide/metformin HCl; 2.5mg/250mg, 2.5mg/500mg, 5mg/500mg; tabs. Adjunct to diet and exercise in type 2 diabetes, as initial therapy or as second-line therapy when response to a sulfonylurea or ...

Highest risk seen with glipizide versus other sulfonylureas and DPP4 inhibitors as second-line therapy. (HealthDay News) — For individuals with type 2 diabetes (T2D) and moderate cardiovascular risk ...

Moderate-risk patients with diabetes treated with a sulfonylurea appear to be at a higher risk of major adverse cardiovascular events than those who receive a dipeptidyl peptidase-4 (DPP-4) inhibitor, ...

Co announces that Mylan Pharmaceuticals has received final approval from the FDA for its Abbreviated New Drug Application for Glipizide and Metformin Hydrochloride Tablets in 2.5 mg/250 mg, 2.5 mg/500 ...

Metformin may be even safer than sulfonylureas. Metformin, the first-line drug of choice for controlling type 2 diabetes, has performed favorably in a study comparing its long-term risks with those of ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dr. Roach: I have Type 2 diabetes. My BMI is 29. My last A1C was 8.4%. I currently take metformin and glipizide. I’ve asked my ...